Voyager Therapeutics

VYGR

Market cap $246M

Voyager Therapeutics maintains a "Strong Buy" rating as it approaches a pivotal 2026 catalyst with tau PET imaging data from its phase 1b study in Alzheimer's disease. Company's anti-tau monoclonal antibody VY7523 demonstrated an excellent safety and PK profile in phase 1 SAD, enabling advancement to phase 1b MAD in early AD patients. Company's robust cash position, projected to fund operations into 2028, is further supported by potential $2.4B in milestone payments and ongoing collaborations.

Voyager Therapeutics, Inc. (VYGR) Presents at Stifel 2026 Virtual CNS Forum Transcript

Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to a loss of $0.59 per share a year ago.

- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 -  - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies to enter clinic H2 2026 - - Advancing Voyager NeuroShuttle™: murine study using anti-amyloid antibody supports sustained brain exposure profile - - Ended 2025 with cash position of $202 million, expected to maintain runway into 2028 - LEXINGTON, Mass.

Voyager Therapeutics, Inc. (VYGR) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript

LEXINGTON, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company will participate in the following upcoming investor conferences: Guggenheim Emerging Outlook: Biotech Summit 2026: Fireside chat at 1:00 p.m.

Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to a loss of $0.16 per share a year ago.

- Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 -  - Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle™ discovery program and small molecule collaboration - - Ended 3Q25 with cash position of $229 million, maintaining runway into 2028 - LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported third quarter 2025 financial and operating results.

CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking traditionally “undruggable” targets by leveraging biomolecular condensates, and Voyager Therapeutics (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, have entered into a drug discovery collaboration and license option agreement. The companies will collaborate to discover and develop novel, selective small molecules for people suffering from amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) with TDP-43 pathology. TDP-43 pathology is common in many neurodegenerative diseases, including over 90% of ALS cases1 and up to 45% of FTD cases2.

Voyager Therapeutics (VYGR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.